Growth hormone insensitivity (Laron syndrome)

Reviews in Endocrine and Metabolic Disorders

Volumn 3, Issue 4, 2002, Pages 347-355

  Laron, Zvi ^a,b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c WHO Collaborating Center for the Study of Diabetes in Youth   (Israel)

Author keywords

GH insensitivity; GH receptor defects; GH resistance; Laron syndrome; Primary IGF I deficiency

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; SOMATOMEDIN C; CARRIER PROTEIN; HUMAN GROWTH HORMONE; SOMATOTROPIN BINDING PROTEIN; SOMATOTROPIN-BINDING PROTEIN;

BONE MATURATION; CLINICAL FEATURE; HORMONE RESISTANCE; HUMAN; LARON SYNDROME; REVIEW; SEXUAL MATURATION; ANTHROPOMETRY; GENETICS; GROWTH DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNDROME;

ANTHROPOMETRY; CARRIER PROTEINS; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECEPTORS, SOMATOTROPIN; SYNDROME;

EID: 0242351229     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020905725012     Document Type: Review

References (92)

1. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 1966;2:152-155.
2. Elders MJ, Garland JT, Daughaday WH, Fisher DA, Whitney JE, Hughes ER. Laron's dwarfism: Studies on the nature of the defect. J Pediatr 1973;83:253-263.
3. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underwood L. Classification of growth hormone insensitivity syndrome. J Pediatr 1993;122:241.
4. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968;4:883-894.
5. Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab 1973;37:819-821.
6. Eshet R, Laron Z, Brown M, Arnon R. Immunological behaviour of hGH from plasma of patients with familial dwarfism and high IR-hGH in a radioimmunoassay system using the cross-reaction between hGH and HCS. Horm Metab Res 1974;6:79-81.
7. Jacobs LS, Sneid DS, Garland JT, Laron Z, Daughaday WH. Receptor-active growth hormone in Laron dwarfism. J Clin Endocrinol Metab 1976;43:403-407.
8. Eshet R, Peleg S, Josefsberg Z, Fuchs C, Arnon R, Laron Z. Some properties of the plasma hGH activity in patients with Laron-type dwarfism determined by a radioreceptor assay using human liver tissue. Horm Res 1985;22:276-283.
9. Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: A possible etiological link in dwarfism. Trans Assoc Am Phys 1969;82:129-138.
10. Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses. J Clin Endocrinol Metab 1971;33:332-342.
11. Eshet R, Laron Z, Pertzelan A, Dintzman M. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. Isr J Med Sci 1984;20:8-11.
12. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Woods WI. Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 1987;330:537-543.
13. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989;86:8083-8087.
14. Laron, Z. Laron type dwarfism hereditary somatomedin deficiency): A review. In: Frick P, Von Harnack GA, Kochsiek GA, Prader A, eds. Advances in Internal Medicine and Pediatrics. Berlin: Springer-Verlag, 1984:117-150.
15. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja: Growth hormone receptor deficiency in an inbred population of Southern Ecuador. N Engl J Med 1990;323:1367-1374.
16. Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, Stein S, Eidson M, Parks JS, Cleveland W. Clinical, biochemical and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab 1997;82:444-451.
17. Yordam N, Kandemir N, Erkul I, Kurdoglu S, Hatun S. A review of the Turkish patients with growth hormone insensitivity (Laron type). Eur J Endocrinol 1995;133:539-542.
18. Maheshwari HG, Clayton PE, Mughal Z, Price DA, Norman M. Laron type dwarfism: The GH-BP positive phenotype. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992, Pediatric and Adolescent Endocrinology, vol. 24. Basel: Karger, 1993;160-166.
19. Desai M, Choksi C, Colaco P, Ambadkar M. Familial growth hormone deficiency (GHD) and growth hormone insensitivity (GHI) in Indian children (Abstract no. 442). Horm Res 1997;48(Suppl 2):90.
20. Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992, Pediatric and Adolescent Endocrinology, vol. 24. Basel: Karger, 1993.
21. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-390.
22. Woods KA, Savage MO. Laron syndrome: Typical and atypical forms. In: Ross RJM, Savage MO, eds. Growth Hormone Resistance. Bailliere's Clin Endocrinol Metab 1996;10:371-387.
23. Pertzelan A, Adam A, Laron Z. Genetic aspects of pituitary dwarfism due to absence of biological activity of growth hormone. Isr J Med Sci 1968;4:895-900.
24. Bass SH, Mulkerrin MG, Wells JA. A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci USA 1991;88:4498-4502.
25. Spencer SA, Hammonds RG, Henzel WJ, Rodriquez H, Waters MJ, Wood WI. Rabbit liver growth hormone receptor and serum binding protein: Purification, characterization and sequence. J Biol Chem 1988;263:7862-7867.
26. Barton DE, Foellmer BE, Woods WI, Francke U. Chromosome mapping of the growth hormone receptor gene in man and mouse. Cytogenet Cell Genet 1989;50:137-141.
27. Kelly PA, Goujon L, Sotiropoulos A, Dinerstein H, Esposito N, Edery M, Finidori J, Postel-Vinay MC. The GH receptor and signal transduction. Horm Res 1994;42:133-139.
28. Parks JS, Faase E. GH and GH-receptor genes. In: Merimee TJ, Laron Z, eds. Growth Hormone, IGF-I and Growth. New Views of Old Concepts, Modern Endocrinology and Diabetes, vol. 4. London: Tel-Aviv Freund Publishing House Ltd., 1996:23-43.
29. de Vos AM, Ultsch M, Kossiakioff AA. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 1992;255:306-312.
30. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993;74:237-244.
31. Horseman NS. Famine to feast-Growth hormone and prolactin signal transducers. Endocrinology 1994;135:1289-1291.
32. Daughaday WH. Are there direct, non-IGF-I-mediated effects of hGH? In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992, Pediatric and Adolescent Endocrinology, vol. 24. Basel: Karger, 1993;338-345.
33. Amselem S, Sobrier ML, Duquesnoy P, Rappaport R, Postel-Vinay MS, Gourmelen M, Dallapicolla B, Goossens M. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. J Clin Invest 1991;87:1098-1102.
34. Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab 1997;82:435-137.
35. Berg MA, Peoples R, Perez-Jurado L, Guevara-Aguirre J, Rosenbloom AL, Laron Z, Milner RDG, Francke U. Receptor mutations and haplotypes in growth hormone receptor deficiency: A global survey and identification of the Ecuadorean E180 splice mutation in an oriental Jewish patient. Acta Paediatr 1994(Suppl. 399):112-114.
36. Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier ML, Valleix S. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Molec Genet 1993;2:355-359.
37. Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, Okimura Y, Abe H, Chihara K. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3705-3709.
38. Counts DR, Cutler GB. Growth hormone insensitivity syndrome due to point deletion and frame shift in the growth hormone receptor. J Clin Endocrinol Metab 1995;80:1978-1981.
39. Berg MA, Argente J, Chernausek S, Gracia R, Guevara-Aguirre J, Hopp M, Perez-Jurado L, Rosenbloom AL, Toledo SPA, Francke U. Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 1993;52:998-1005.
40. Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U. Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutation 1992;1:124-134.
41. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: Extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997;10:265-274.
42. Woods KA, Fraser NC, Postel-Vinay MC, Savage MO, Clark AJL. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996;81:1686-1690.
43. Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, Chihara K. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998;83:531-537.
44. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, Norman MR. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nature Genet 1997;16:13-14.
45. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goosens M. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 1989;321:989-995.
46. Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 1998;83:2554-2561.
47. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M, Amselem S. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. Embo J 1994;13:1386-1395.
48. Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab 1993;76:54-59.
49. Duquesnoy P, Sobrier ML, Amselem S, Goossens M. Defective membrane expression of human growth hormone (GH) receptor causes Laron-type GH insensitivity syndrome. Proc Natl Acad Sci USA 1991;88:10272-10276.
50. Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: Response to IGF-I treatment. Isr J Med Sci 1993;29:757-763.
51. Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 1986;77:1817-1823.
52. Baumann G, Stolar MN, Amburn K, Barsano CP, DeVries BC. A specific GH-binding protein in human plasma:Initial characterization. J Clin Endocrinol Metab 1986;62:134-141.
53. Silbergeld A, Lazar L, Erster B, Keret R, Tepper R, Laron Z. Serum growth hormone binding protein activity in healthy neonates, children and young adults-Correlation with age, height and weight. Clin Endocrinol 1989;31:295-303.
54. Laron Z, Klinger B, Erster B, Silbergeld A. Serum GH binding protein activity identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol 1989;121:603-608.
55. Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995;80:1526-1531.
56. Laron Z. Deficiencies of growth hormone and somatomedins in man. In: Cohen MP, Foa PP, eds. Special Topics in Endocrinology and Metabolism, vol. 5. New York: Alan R. Liss 1983:149-199.
57. Laron Z, Pertzelan A, Karp M, Keret R, Eshet R, Silbergeld A. Laron syndrome-A unique model of IGF-I deficiency. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992, Pediatric and Adolescent Endocrinology, vol. 24. Basel 1993;3-23.
58. Scharf A, Laron Z. Skull changes in pituitary dwarfism and the syndrome of familial dwarfism with high plasma immunoreactive growth hormone. A roentgenologic study. Horm Metab Res 1972;4:93-97.
59. Konfino R, Pertzelan A, Laron Z. Cephalometric measurements of familial dwarfism and high plasma immunoreactive growth hormone. Am J Orthod 1975;68:196-201.
60. Laron Z, Klinger B, Grunebaum M. Laron type dwarfism. Special feature-Picture of the Month. Am J Dis Child 1991;145:473-474.
61. Lurie R, Ben-Amitai D, Laron Z. Laron syndrome/growth hormone (GH) insensitivity/a unique model to explore the effect of insulin like growth factor I (IGF-I) deficiency on human hair. Br J Dermatol 2003 (in press).
62. Laron Z. Consequences of not treating children with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2001;14(Suppl. 5):1243-1248.
63. Laron Z. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab 1999;12:231-249.
64. Kornreich L, Horev G, Schwarz M, Karmazyn B, Laron Z. Laron syndrome abnormalities: Spinal stenosis, os odontoideum, degenerative changes of the attanto-odontoid joint, and a small oropharynx. Am J Neuroradiology 2002;23:625-631.
65. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993;68:768-770.
66. Laron Z, Klinger B. Body fat in Laron syndrome patients: Effect of insulin-like growth factor treatment. Horm Res 1993;40:16-22.
67. Brat O, Ziv I, Klinger B, Avraham M, Laron Z. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron Syndrome. Horm Res 1997;47:45-48.
68. Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol 2000;85:209-213.
69. Laron Z, Gaides M, Scheinowitz M, Wagner R, Ben-Dov I. Reduced maximal aerobic capacity in patients with primary growth hormone insensitivity (Laron syndrome). Program and Abstracts, 82nd Annual Meeting Endocrine Society June 2000; (Abstract no. 1933), Toronto, Canada, 2000;482.
70. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: Preliminary results. Clin Endocrinol 1994;41:631-638.
71. Laron Z, Sarel R. Penis and testicular size in patients with growth hormone insufficiency. Acta Endocrinol 1970;63:625-633.
72. Laron Z, Sarel R, Pertzelan A. Puberty in Laron type dwarfism. Eur J Pediatr 1980;134:79-83.
73. Laron Z, Lazar L, Klinger B. Growth hormone, insulin-like growth factor I and brain growth and function. In: Castells S, Wisniewski KE, eds. Growth Hormone Treatment in Down's Syndrome, Chichester: Wiley and Sons, 1993;151-161.
74. Dagan Y, Abadi J, Lifschitz A, Laron Z. Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Hormone & IGF Res 2001;11:247-249.
75. Galatzer A, Aran O, Nagelberg N, Rubitzek J, Laron Z. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, eds. Lessons from Laron Syndrome (LS) 1966-1992, Pediatric and Adolescent Endocrinology, vol. 24. Basel: Karger, 1993;53-60.
76. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994;8:684-688.
77. Klinger B, Jensen LT, Silbergeld A, Laron Z. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996;45:423-429.
78. Laron Z, Pertzelan A, Doron M, Assa S, Keret R. The effect of dihydrosomatostatin in dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res 1977;9:338-339.
79. Laron Z, Klinger B, Jensen LT, Erster B. B iochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991;35:145-150.
80. Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein 3 in patients with LTD: Effect of exogenous rIGF-I. Clin Endocrinol 1992;36:301-304.
81. Laron Z, Suikkari AM, Klinger B, Silbergeld A, Pertzelan A, Seppala M, Koivisto VA. Growth hormone and insulin-like growth factor regulate insulin-like growth factor binding protein in Laron type dwarfism, growth hormone deficiency and constitutional growth retardation. Acta Endocrinol 1992;127:351-358.
82. Silbergeld A, Klinger B, Schwartz H, Laron Z. Serum prolactin in patients with Laron-type dwarfism: Effect of insulin-like growth factor I. Horm Res 1992;37:160-164.
83. Laron Z. Insulin-like growth factor 1 (IGF-1): A growth hormone J Clin Pathol: Mol Pathol 2001;54:311-316.
84. Laron Z. Growth hormone resistance (Laron syndrome). In: Chrousos G, ed. Hormone Resistance and Hypersensitivity States, New York: Lippincott Williams & Wilkins, 2002;251-267.
85. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron Syndrome. J Pediatr Endocrinol Metab 1995;8:149-158.
86. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P for the Working Group on Growth Hormone Insensitivity Syndromes. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Horm Res 1999;51:128-134.
87. Laron Z, Klinger B. Comparison of the growth-promoting effects of insulin-like growth factor I and growth hormone in the early years of life. Acta Paediatr 2000;88:38-41.
88. Backeljauw PF, Underwood LE, and The GHIS Collaborative Group. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study. J Clin Endocrinol Metab 2001;86:1504-1510.
89. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258-1261.
90. Laron Z. Somatomedin-1 (recombinant insulin-like growth factor-I). Clinical pharmacology and potential treatment of endocrine and metabolic disorders. Biodrugs 1999;11:55-70.
91. Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay MC, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO. Phenotype:genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-3535.
92. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999;84:4436-4443.